Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94,036Revenue $M25,711Net Margin (%)9.9Z-Score2.4
Enterprise Value $M99,242EPS $2.0Operating Margin %14.4F-Score4
P/E(ttm))45.6Cash Flow Per Share $9.7Pre-tax Margin (%)12.7Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %7.6Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %-9.0Current Ratio0.9Lower Leverage y-yY
Price/Cash Flow5.0y-y EBITDA Growth Rate %-22.6ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.8Insider Buy (3m)0ROE % (ttm)11.0Less Shares Outstanding y-yN
Payout Ratio %172Shares Outstanding M1,263ROI % (ttm)12.6Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 74.5216%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 74.5216%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 74.5216%New holding, 95518 sh.95,518
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 74.5216%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 74.5237%Reduce -40.32%106,975
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 74.5237%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 74.5248%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 74.5248%Reduce -81.87%68,000
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 74.5246%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 74.5246%Sold Out0
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 74.5257%Reduce -38.8%932,000
AZNCharles Brandes 2012-12-31 Buy 1.2%$44.34 - $48.9
($46.77)
$ 74.5259%New holding, 2188735 sh.2,188,735
AZNJohn Hussman 2012-12-31 Reduce-0.56%$44.34 - $48.9
($46.77)
$ 74.5259%Reduce -24.49%1,523,000
AZNDavid Dreman 2012-12-31 Reduce-0.2%$44.34 - $48.9
($46.77)
$ 74.5259%Reduce -52.4%152,504
AZNJoel Greenblatt 2012-12-31 Reduce-0.12%$44.34 - $48.9
($46.77)
$ 74.5259%Reduce -31.34%83,972
AZNJoel Greenblatt 2012-09-30 Add0.12%$44.91 - $48.35
($46.83)
$ 74.5259%Add 42.7%122,294
AZNCharles Brandes 2012-09-30 Sold Out -1.2%$44.91 - $48.35
($46.83)
$ 74.5259%Sold Out0
AZNDavid Dreman 2012-09-30 Reduce-0.11%$44.91 - $48.35
($46.83)
$ 74.5259%Reduce -24.31%320,376
AZNJoel Greenblatt 2012-03-31 Add0.12%$44.18 - $48.58
($42.78)
$ 74.5274%Add 66.8%74,557
AZNJoel Greenblatt 2011-12-31 Buy 0.25%$42.53 - $49.89
($46.11)
$ 74.5262%New holding, 44699 sh.44,699
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Joel Greenblatt 2014-03-3195,5180.010.09New Buy
AZN John Hussman 2014-03-31228,0000.021.1+714.29%
AZN David Dreman 2014-03-31135,4390.010.68+26.61%
AZN Charles Brandes 2014-03-311,333,8940.111.1-46.73%
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 
      Profits Are Good, Cures Are Better: The Pharmaceutical Industry Oct 08 2013 


      More From Other Websites
      Eyes Down For AstraZeneca plc Results Jul 25 2014
      Eyes Down For AstraZeneca plc Results Jul 25 2014
      Bristol-Myers (BMY) Beats on Q2 Earnings, Maintains Outlook Jul 24 2014
      [video] Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs Jul 24 2014
      Bristol-Myers profit tops forecasts, helped by newer drugs Jul 24 2014
      Pfizer Needs to Do a Deal, Analyst Says Jul 24 2014
      Bristol 2Q net drops on lower drug sales, charges Jul 24 2014
      Bristol 2Q net drops on lower drug sales, charges Jul 24 2014
      This Eye-Popping Chart Of Ex-US Companies Shows Why People Are Freaking Out About 'Tax Inversions' Jul 24 2014
      Glaxo (GSK) Slips on Disappointing Q2 Earnings, Cuts View Jul 24 2014
      [video] Caterpillar CEO sees mining 'green shoots' Jul 24 2014
      [video] Eli Lilly looking for smaller acquisitions: CEO Jul 24 2014
      [video] Results hurt by patent expirations: Eli Lilly CEO Jul 24 2014
      Should You Buy GlaxoSmithKline plc Or AstraZeneca plc? Jul 23 2014
      Should You Buy GlaxoSmithKline plc Or AstraZeneca plc? Jul 23 2014
      Allergan, a Valeant Takeover Target, Plans 1,500 Job Cuts Jul 22 2014
      European shares bounce back, helped by earnings reports Jul 22 2014
      European shares bounce back as Ukraine tension ease Jul 22 2014
      European shares up as Ukraine rebels allow improved access Jul 22 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide